Ligand Pharmaceuticals
LGND
LGND
298 hedge funds and large institutions have $3.35B invested in Ligand Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 123 increasing their positions, 99 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
0.02% less ownership
Funds ownership: 187.54% → 187.52% (-0.02%)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
61% less call options, than puts
Call options by funds: $7.11M | Put options by funds: $18.2M
Holders
298
Holding in Top 10
7
Calls
$7.11M
Puts
$18.2M
Top Buyers
| 1 | +$21.9M | |
| 2 | +$15.8M | |
| 3 | +$14.7M | |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$12.7M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$11M |
Top Sellers
| 1 | -$61M | |
| 2 | -$18.3M | |
| 3 | -$15.8M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$14M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$12.9M |